Archives: Speakers

Satha Thillaiampalam has been leading various responsibilities within the biopharmaceutical industry. Throughout his twenty-year career as a Biostatistician and Statistical Programmer, he has led numerous strategic initiatives involving cross functional teams to continuously improve systems, processes, and governance. In his current role, he leads the processes and infrastructure activities for oncology biostatistics department within Lilly. His key interests are optimizing operational efficiency and developing high performing systems by leveraging advancements in technology and standards.

I started my career at Everest Clinical Research in CDM. I later joined Gilead’s CDM team focusing on infectious disease therapeutic area. I transitioned to commercial (sales analytics) for almost 3 years to better understand the lifecycle of drug post approval. I decided to return to CDM and joined Biomarin to better understand rare diseases. Post Biomarin, I spent some time at Nektar before landing the position at Denali, focusing on rare disease trials again.

Dr. Hyunjae Ryan Kim is currently the leader of a team at Gilead Sciences, which specializes in oncology genomics analytics. He is responsible for developing multimodal AI algorithms and applications used in clinical development for oncology. Additionally, he researches how to improve cancer treatment using deep learning and multi-omics data integration by modulating tumor microenvironments.

Dr. Kim previously held the associate director of pediatric oncology bioinformatics position at the Texas Children’s Cancer Center at Baylor College of Medicine (BCM). Before joining BCM, he was a senior computational biologist at the Memorial Sloan Kettering Cancer Center. Dr. Kim and his team developed routine genomic profiling systems (MSK-IMPACT) and matching treatment options for all patients in MSKCC. He also served as research faculty at the Rockefeller University, where he built systems to decipher epigenetic codes and transcriptional controls from multi-omics data with C. David Allis and Thomas Tuschl. Dr. Kim completed his postdoctoral training in Systems Biology at Columbia University Medical Center.